tumorigenesis
In agreement with this hypothesis, CRISPR-mediated deletion of SNORD50A and SNORD50B in KRAS-mutant tumor cells enhanced tumorigenesis, and SNORD50A and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types.
In agreement with this hypothesis, CRISPR-mediated deletion of <span class="gene" id="26595770-7-63-71">SNORD50A</span> and SNORD50B in KRAS-mutant tumor cells enhanced <span class="disease" id="26595770-7-121-134">tumorigenesis</span>, and <span class="gene" id="26595770-7-140-148">SNORD50A</span> and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types.